LogicBio Therapeutics
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 3.0m | 4.0m | 571m | 287m | 43.0m | 225m |
| % growth | - | - | 33 % | 14175 % | (50 %) | (85 %) | 423 % |
| EBITDA | (43.0m) | (54.0m) | (358m) | (392m) | (324m) | - | - |
| % EBITDA margin | - | (1800 %) | (8950 %) | (69 %) | (113 %) | - | - |
| Profit | (36.0m) | (32.0m) | (46.0m) | (384m) | (317m) | - | - |
| % profit margin | - | (1067 %) | (1150 %) | (67 %) | (110 %) | - | - |
| EV / revenue | - | 81.0x | 5.5x | 0.0x | - | - | - |
| EV / EBITDA | -3.8x | -4.5x | -0.1x | -0.1x | - | - | - |
| R&D budget | - | 222m | 208m | 194m | 152m | - | - |
| R&D % of revenue | - | 7400 % | 5200 % | 34 % | 53 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$4.0m | Series A | ||
$45.0m | Series B | ||
| N/A | $70.0m Valuation: $294m | IPO | |
$20.0m | Post IPO Debt | ||
N/A | Post IPO Equity | ||
* | N/A | Acquisition | |
| Total Funding | CAD66.8m | ||
Related Content
Recent News about LogicBio Therapeutics
EditLogicBio Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines to treat rare and serious genetic diseases. The company aims to provide one-time treatments that offer long-lasting results, significantly improving the lives of young patients. LogicBio operates in the healthcare and biotechnology market, specifically targeting rare genetic disorders that currently have limited treatment options.
The company's business model revolves around harnessing the natural DNA repair process to create precise, stable, and durable therapies. This approach involves using advanced genetic engineering techniques to correct genetic defects at their source. By focusing on one-time treatments, LogicBio aims to reduce the need for ongoing medical interventions, thereby offering a more efficient and potentially cost-effective solution for patients and healthcare providers.
LogicBio primarily serves patients with rare genetic diseases, a market that is often underserved due to the complexity and high costs associated with developing treatments for small patient populations. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to bring its therapies from the research stage to clinical application.
Revenue generation for LogicBio comes from several streams, including partnerships with larger pharmaceutical companies, grants, and potential future sales of its genetic therapies. By presenting at industry conferences like the Jefferies Virtual Healthcare Conference, LogicBio aims to attract investment and foster collaborations that can accelerate the development and commercialization of its treatments.
In summary, LogicBio Therapeutics is dedicated to delivering innovative genetic medicines that offer hope and tangible benefits to patients with rare genetic diseases. The company's focus on one-time, durable treatments positions it as a promising player in the biotechnology sector.
Keywords: genetic medicine, rare diseases, DNA repair, one-time treatment, biotechnology, young patients, durable therapies, healthcare, genetic engineering, clinical operations.